The Effect of Moringa oleifera Leaves and VipAlbumin® on The Immune System of Diabetes Mellitus Balb/C Mice Model
DOI:
https://doi.org/10.21776/ub.jels.2019.009.03.05Abstract
Diabetes Mellitus is known as a disease grown worldwide rapidly prevalent day by day. This disease caused by a chronic hyperglycemic condition and also glucose intolerance resulting from defects in insulin secretion, insulin action, or both. Moringa oleifera is one of the plants used in most developing countries for traditional medicine for treating diabetes. In this research, Moringa oleifera mixed with VipAlbumin®, taken from snakehead fish albumin. Albumin found as an antioxidant against ROS. This research aimed to evaluate the effect of Moringa oleifera mixed with VipAlbumin® supplement towards the profile changing of T-cell, (CD4+ CD8+) B220+, CD4+ IFN-γ, and TNF-α. The experiments were done by dividing Balb/c mice into five groups and induced with 100 mg.BW-1 STZ. Afterward, the mix of Moringa oleifera and VipAlbumin® orally administrated into five different doses. Negative control contains of healthy mice, Positive dose administrated with 145 mg.kg bw-1 STZ, Dose 1 of 100 mg.kg bw-1 (Mo) + 416.25 mg.kg bw-1 (A), Dose 2 of 150 mg.kg bw-1 (Mo) + 208.15 mg.kg bw-1 (A), Dose 3 of 50 mg.kg bw-1 (Mo) + 624.375 mg.kg bw-1 (A). One way ANOVA was applied to analyze the data with p-value 0.05% and combined with Tukey test using SPSS version 16 for Windows. The results showed that a relative number of CD4 and CD8 T cells decreased in dose 3 of Moringa oleifera and Albumin, as well as B220 in dose 3 gave a significant decreased compared to healthy mice (p<0.05). The inflammation showed decreasing after treatment with dose 3 of Moringa oleifera and albumin extract. Taken together that proinflammatory cytokines decreased after treatment compared to a positive group.
Keywords: Albumin, Inflammation, Moringa oleifera, T cells.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 The Journal of Experimental Life Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).